• $15 million two tranche placement to sophisticated and professional investors
• Funds to support production development, clinical/R&D, SAPPHIRE study, and working capital
• Placement priced at $0.73 per share, representing a 15.1% discount to last trading price

ARTRYA Ltd, a medical technology company, has announced a $15 million capital raise through a two-tranche placement to sophisticated and professional investors. The placement will consist of approximately $5 million under the company's existing placement capacity, and an additional $10 million subject to shareholder approval. The offer price is $0.73 per share, representing a 15.1% discount to the last trading price on ASX of $0.86 on 11 February 2025, and a 10.4% discount to the 5-day VWAP of $0.815. The funds raised will be used to support production development ($7.0 million), clinical, R&D and regulatory activities ($3.6 million), the SAPPHIRE study ($2.0 million), and working capital and other costs ($2.4 million). Petra Capital is acting as Sole Lead Manager and Sole Bookrunner to the placement.